FindTrial
Sign In

MRS

DEVICE6 trials

Sponsors

National Cancer Institute (NCI), Alberta Health services, AHS Cancer Control Alberta, Massachusetts General Hospital, Hvidovre University Hospital

Conditions

Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaBariatric SurgeryBrain Lesion (General)Breast CancerGlioblastomaMedication Reconciliation

Phase 2

MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
CompletedNCT00902577
National Cancer Institute (NCI)Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Start: 2009-08-24End: 2018-01-31Updated: 2019-04-08

Unknown Phase

Pharmacist Discharge Medication Reconciliation Study
CompletedNCT01226589
Alberta Health servicesMedication Reconciliation
Start: 2007-10-31End: 2008-10-31Target: 50Updated: 2011-04-19
Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer
CompletedNCT01428739
AHS Cancer Control AlbertaBreast Cancer
Start: 2007-12-31End: 2014-09-30Updated: 2017-01-25
Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
CompletedNCT02843230
Massachusetts General HospitalGlioblastoma
Start: 2016-08-01End: 2022-01-31Updated: 2022-04-08
Fat Absorption and Metabolism After Roux-en-Y Gastric Bypass
CompletedNCT04859816
Hvidovre University HospitalBariatric Surgery
Start: 2021-04-01End: 2022-05-01Updated: 2022-08-23
Role of MRS in Brain Lesions
NCT05565690
Assiut UniversityBrain Lesion (General), Mrs
Start: 2022-10-01End: 2024-11-01Target: 64Updated: 2022-10-04

Related Papers

Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma
Radiology2021-11-0916 citations
ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI.
Journal of Clinical Oncology2015-05-201 citations